10-Q: Tilray Brands Narrows Losses, Boosted by Cannabis & Distribution

Tilray Brands reported a significant reduction in net loss for the quarter ended November 30, 2025, driven by growth in its cannabis and distribution segments, despite declines in its beverage business.

Summary

• Net revenue increased by 3% to $217.5 million for the three months ended November 30, 2025, compared to $211.0 million in the prior year period.
• Net loss significantly improved by 49% to $(43.5) million for the three months ended November 30, 2025, from $(85.3) million in the prior year.
• Operating loss improved by 47% to $(22.3) million for the three months ended November 30, 2025, from $(42.2) million in the prior year.
• Gross profit decreased by 6% to $57.5 million for the three months ended November 30, 2025, from $61.2 million in the prior year.
• Adjusted EBITDA decreased by 7% to $8.4 million for the three months ended November 30, 2025, compared to $9.0 million in the prior year.
• The company completed its At-the-Market (ATM) program, issuing 6,777,224 shares and generating $73.1 million in net proceeds.
• A one-for-ten reverse stock split became effective on December 2, 2025, retrospectively adjusting all share amounts.
• The company exchanged $5.0 million of its TLRY 27 Notes for cancellation, issuing 1,259,182 shares of Common Stock and paying $6,000 in cash, resulting in a $495,000 gain.
• 620,900 warrants were exercised between September 5-15, 2025, generating $2.4 million in cash, with no warrants remaining outstanding.
• The Fort Collins, CO partially vacant warehouse facility was classified as held for sale, with a $1.8 million reduction in fair value recorded; the sale was completed subsequent to the reporting period.
• Restructuring costs decreased significantly by 86% to $1.0 million for the three months ended November 30, 2025, from $6.9 million in the prior year.
• The Montauk Brewing Company contingent consideration was reassessed with a 0% probability of achievement, resulting in a $15.0 million change in fair value recognized as income.

Sentiment

Score: 6

Explanation: The company showed significant improvement in net and operating losses, driven by strong performance in international cannabis and distribution. However, the core beverage segment continues to struggle, and overall gross profit declined. The completion of the ATM program and potential for U.S. cannabis rescheduling are positive, but regulatory uncertainties and competitive pressures remain.

Positives

• Net loss significantly improved by 49% to $(43.5) million for the three months ended November 30, 2025, compared to $(85.3) million in the prior year.
• Operating loss improved by 47% to $(22.3) million for the three months ended November 30, 2025, from $(42.2) million in the prior year.
• Total net revenue increased by 3% to $217.5 million for the three months ended November 30, 2025.
• International cannabis revenue grew by 36% to $20.2 million for the three months ended November 30, 2025, driven by growth in Germany and expansion into emerging medical markets.
• Distribution revenue increased by 26% to $85.3 million for the three months ended November 30, 2025, due to competitive pricing, focus on high-velocity SKUs, and favorable foreign exchange impacts.
• Canadian adult-use cannabis revenue increased by 6% to $62.4 million for the three months ended November 30, 2025, attributed to sales growth in flower and non-infused pre-roll categories and re-entry into price-compressed categories.
• Restructuring costs decreased substantially by 86% to $1.0 million for the three months ended November 30, 2025, reflecting reduced integration expenses.
• A $15.0 million gain was recognized from the change in fair value of contingent consideration related to the Montauk Brewing acquisition, as the earn-out is no longer expected to be achieved.
• The ATM program was completed, generating $73.1 million in net proceeds, enhancing liquidity.
• Long-term debt decreased to $138.7 million as of November 30, 2025, from $148.5 million as of May 31, 2025.
• Total liabilities decreased to $552.1 million as of November 30, 2025, from $584.8 million as of May 31, 2025.
• Cash and marketable securities increased to $291.6 million as of November 30, 2025, from $252.2 million as of May 31, 2025.

Negatives

• Beverage segment net revenue decreased by 21% to $50.1 million for the three months ended November 30, 2025, due to category challenges, competitive pressures, and portfolio optimization efforts.
• Beverage gross margin declined to 31% for the three months ended November 30, 2025, from 40% in the prior year, impacted by lower-margin acquisitions, declining overhead utilization, and delays in Project 420 benefits.
• Wholesale cannabis revenue decreased significantly by 80% to $1.3 million for the three months ended November 30, 2025, due to strategic redirection of volume to other markets.
• Canadian medical cannabis revenue decreased by 7% to $6.2 million for the three months ended November 30, 2025, primarily due to uninsured patient attrition to the adult-use market.
• Adjusted EBITDA decreased by 7% to $8.4 million for the three months ended November 30, 2025.
• The company recognized a foreign exchange loss of $10.3 million for the three months ended November 30, 2025.
• An unrealized loss of $172,000 was recognized on digital assets (Bitcoin) as of November 30, 2025.
• A $1.8 million loss was recorded on the change in fair value of assets held for sale related to the Fort Collins, CO facility.

Risks

• Failure to achieve expected revenue or benefits from craft beer operations acquired in fiscal years 2024 and 2025.
• Difficulties integrating operations and realizing expected benefits of recent acquisitions, including the Craft brands acquisitions.
• The cannabis business is dependent upon regulatory approvals and licenses, ongoing compliance and reporting obligations, and timely renewals.
• Government regulation is evolving, including potential regulatory developments in the United States to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act, with significant uncertainty regarding scope, timing, and ultimate impact.
• New U.S. federal legislation enacted in November 2025 banned the production or sale of hemp-derived cannabis, including Delta-9, effective November 12, 2026, which could impact HD-D9 beverages.
• Potential modifications to existing regulatory frameworks outside of North America, as well as uncertainties and potential delays in receiving required export/import permits in Europe and Australia.
• Intense competition, including from the illicit cannabis market, and anticipated increase in competition.
• Adverse changes or developments affecting production and processing facilities may have an adverse impact on the business.
• Regulations constrain the ability to market and distribute products in Canada.
• United States regulations relating to hemp-derived CBD products, Delta-9 products, and medical cannabis products are new and rapidly evolving, and changes may not develop in the timeframe or manner most favorable to business objectives.
• Changes in consumer preferences or public attitudes about alcohol could decrease demand for beverage products.
• SweetWater, Breckenridge, Montauk, and recently-acquired craft beer brands each face substantial competition in the beer industry or the broader market for beverage products.
• Exposure to litigation, arbitration, and demands, which could result in significant liability and costs, and impact resources and reputation.
• Material adverse effects from the imposition of duties and tariffs and other trade barriers and retaliatory countermeasures.
• Additional impairments of goodwill and impairments of long-lived assets could have a material adverse impact on financial results.
• Limited operating history and a history of net losses, with no guarantee of achieving or maintaining profitability in the future.
• Strategic alliances and other third-party business relationships may not achieve the intended beneficial impact and expose the company to risks.
• Inability to successfully identify and execute future acquisitions, dispositions or other equity transactions or to successfully manage the impacts of such transactions on operations.
• Risks inherent in an agricultural business, including the risk of crop failure.
• Dependence on recurring customers for a substantial portion of revenue; failure to retain or expand customer relationships or reduced purchases could significantly decline revenue.
• Products may be subject to recalls for a variety of reasons, which could require significant management and capital resources.
• Significant interruptions in access to certain supply chains for key inputs such as raw materials, supplies, electricity, water and other utilities may impair operations.
• Management may not be able to successfully establish and maintain effective internal controls over financial reporting.
• The price of common stock in public markets has experienced and may continue to experience severe volatility and fluctuations.
• The volatility of stock and the stockholder base may hinder or prevent engagement in beneficial corporate initiatives.
• Inability to raise the funds necessary to settle conversions of convertible securities in cash or to repurchase the convertible securities upon a fundamental change.
• The cryptocurrency strategy faces high risk and uncertainty in light of market volatility and an evolving regulatory landscape.
• Exposure to financial losses and operational risks due to the decision to self-insure certain real property assets.

Future Outlook

The company anticipates continued evolution in the Canadian cannabis industry, with price compression expected to persist. In Europe, cannabis legalization (medical and adult-use) is expected to gain traction, albeit slowly, with Germany's new regulations serving as a catalyst. The company expects to complete its Project 420 synergy optimization plan in the fourth quarter of fiscal 2026. U.S. federal cannabis rescheduling is viewed as a significant long-term growth opportunity, potentially leading to the launch of a medical cannabis platform in 2026, though regulatory uncertainties remain. The company intends to continue opportunistically purchasing or exchanging equity for its TLRY 27 Notes prior to maturity.

Management Comments

• We continue to focus on developing strong capabilities in data analytics and consumer insights, drive category management leadership and assess opportunities for the introduction of new categories, products and entries into new geographies.
• We are relentlessly focused on managing our cost structure and expenses in order to maintain our strong financial position.
• Our experienced leadership team provides a strong foundation to accelerate our growth.
• We believe that new regulations could evolve prior to November 2026 to permit continued sales of HD-D9 beverages under the recent executive order directing the U.S. rescheduling of cannabis products.
• We continue to enhance our global supply chain and increase our cultivation footprint to support the growing demand for our product in both Canadian and international cannabis markets.
• We continue to opportunistically redirect certain inventories to international cannabis markets, which is expected to generate higher margin sales.
• We believe that Tilray remains uniquely well-positioned to maintain and gain significant market share in the markets in which we participate.
• We are proudly pioneering the effort to further understand the therapeutic value of cannabis through the guidance of its independent Medical Advisory board and through partnerships with leading research institutions globally.
• We believe that these assets and attributes, combined with our ability to navigate complex regulatory environments, will continue to drive our leadership in international medical markets and allow us to successfully enter new markets as they adopt medical cannabis and potentially adult-use regulations and may also serve to support a potential U.S. participation.
• We intend to leverage our proven compliance infrastructure, scientific knowledge, and operational scale to expand responsibly in the U.S. market, introducing medical-grade cannabis products in targeted therapeutic formats.
• We are committed to optimizing our capital structure and enhancing financial flexibility as we intend to continue to opportunistically purchase or exchange equity for the TLRY 27 Notes prior to their underlying maturity date in June 2027, subject to market conditions.

Industry Context

The beverage alcohol industry faces evolving consumer trends, including a shift towards reduced alcohol consumption and increased demand for ready-to-drink cocktails, prompting Tilray's diversification into non-alcoholic craft beer, sparkling waters, and clean label energy drinks. The Canadian cannabis market remains nascent and highly competitive with approximately 1,000 Licensed Producers, leading to persistent price compression, especially in specific categories. Internationally, the medical cannabis market is developing, with Germany's recent regulations acting as a catalyst for broader European policy changes. The U.S. federal cannabis rescheduling initiative represents a significant potential shift, aligning with Tilray's expertise in regulated medical cannabis. The wellness market continues to grow, driven by demand for natural and organic food and beverages.

Comparison to Industry Standards

• The Canadian cannabis market experiences fierce competition among approximately 1,000 Licensed Producers, intensifying price compression, which Tilray is navigating by optimizing its cost structure and re-entering previously margin-prohibitive categories.
• Tilray's international cannabis business benefits from its EU-GMP cultivation facilities in Portugal and Germany, and a fully owned route-to-market in Germany, Australia, and Italy, positioning it as a global leader in pharmaceutical-grade medical cannabis, a standard not all competitors meet.
• Breckenridge Distillery's multiple prestigious accolades, including three Icons of Whisky awards and ten Best American Blended Whiskey honors, demonstrate its premium craftsmanship and award-winning quality within the spirits category, distinguishing it from many competitors.
• The company's strategic focus on value-added innovation in the wellness segment, such as high protein super-seeds and better-for-you breakfast products, aligns with broader industry trends towards natural and organic food and beverages, positioning it competitively against health-focused brands.

Legal Proceedings

• The company is subject to various legal proceedings and disputes in the ordinary course of business.
• Litigation accruals totaled $12.0 million as of November 30, 2025, and $12.4 million as of May 31, 2025.
• Management believes that appropriate legal reserves have been established and that incremental liabilities from pending legal proceedings are not expected to have a material adverse effect on consolidated financial position, results of operations, or cash flows, though ultimate resolution could be material.

Related Party Transactions

• On October 9, 2025, Tilray acquired a promissory note of $14,821 from Double Diamond Holdings Ltd. (DDH), a joint venturer with Tilray's subsidiary Aphria Inc. in Aphria Diamond. As consideration, Tilray issued 861,707 shares of its Common Stock to DDH.

Stakeholder Impact

• **Shareholders**: The reverse stock split (1-for-10) aims to increase share price, potentially improving market perception and liquidity, though proportional ownership remains unchanged. Improved net loss and operating performance could be positive, but declining gross profit and beverage segment struggles may concern some. The completion of the ATM program diluted existing shareholders but provided capital for strategic initiatives. The potential for U.S. cannabis legalization offers long-term growth prospects.
• **Employees**: Restructuring costs include employee termination severance and benefits related to the reorganization of the Canadian cannabis commercial function, indicating job impacts in certain areas. Stock-based compensation remains an important part of the compensation strategy.
• **Customers**: Strategic initiatives like SKU optimization in the beverage segment may lead to changes in product availability. Innovation in non-alcoholic beverages and medical cannabis aims to meet evolving consumer preferences. Delays in international cannabis permits could temporarily affect product availability in some markets.
• **Creditors**: Repayment of long-term debt and opportunistic exchanges of convertible notes reduce overall debt obligations, potentially improving creditworthiness. The self-insurance model for real property assets shifts risk to the company, which could impact financial stability if significant losses occur.
• **Suppliers**: Supply chain disruptions and tariffs on input materials (aluminum, hops, barley, malt, vape componentry) could impact supplier relationships and costs.

Next Steps

• Complete the Project 420 synergy optimization plan in the fourth quarter of fiscal 2026.
• Continue to opportunistically redirect inventories to international cannabis markets to generate higher margin sales.
• Continue to evaluate the wholesale cannabis market and opportunistically sell where it makes sense.
• Monitor and adapt to evolving U.S. federal legislation regarding hemp-derived Delta-9 beverages.
• Monitor U.S. federal cannabis rescheduling developments and prepare for potential launch of a medical cannabis platform in 2026.
• Continue to invest in marketing, promotion, and infrastructure for recently acquired beverage brands.
• Continue to optimize capital structure and enhance financial flexibility, including opportunistic purchases or exchanges of equity for TLRY 27 Notes.

Key Dates

Recommendation

Tilray Brands demonstrated significant progress in narrowing its net and operating losses, driven by robust growth in its international cannabis and distribution segments. The completion of the ATM program and the strategic reduction in long-term debt enhance liquidity and financial flexibility. However, the persistent decline in the beverage segment's revenue and gross margin, coupled with ongoing price compression in the Canadian cannabis market, present headwinds. While the potential for U.S. federal cannabis rescheduling offers substantial long-term upside, its timing and regulatory specifics remain uncertain. The company's self-insurance strategy introduces new financial risks. Given the mixed performance across segments and the balance of opportunities and risks, a 'hold' recommendation is appropriate. Investors should monitor the execution of Project 420, developments in U.S. cannabis regulation, and the performance of the beverage segment for clearer directional signals.

Keywords

Cannabis, Beverage Alcohol, Distribution, Wellness, SEC Filing, 10-Q, Quarterly Report, Tilray Brands, TLRY, Financial Results, Net Loss, Revenue, Adjusted EBITDA, Reverse Stock Split, Craft Beer, Medical Cannabis, Adult-Use Cannabis, International Cannabis, Project 420, Regulatory Risk, Hemp-Derived Delta-9, U.S. Cannabis Rescheduling, Digital Assets, Bitcoin, Liquidity, Capital Resources